NKTR - ネクタ―・セラピュ―ティクス (Nektar Therapeutics) ネクタ―・セラピュ―ティクス

 NKTRのチャート


 NKTRの企業情報

symbol NKTR
会社名 Nektar Therapeutics (ネクタ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ネクター・セラピューティクス(Nektar Therapeutics)は医薬品を発見・開発するバイオ医薬品企業である。同社の新規治験薬の研究開発パイプラインには、がん、自己免疫疾患、慢性疼痛の治療が含まれる。同社は化学物質のプラットフォームを活用して新薬の候補を発見・設計する。薬物候補は既知の作用機序を標的とする新しい分子実体の開発を可能にするように設計されたポリマーコンジュゲート技術プラットフォームを利用する。同社のプログラムには、免疫腫瘍学(I-O)、免疫学、Pain-NKTR-181、および腫瘍学ONZEALDが含まれる。同社は細胞傷害性T細胞やナチュラルキラー(NK)細胞などの主要な免疫細胞の活性を直接的または間接的に調節してその数を増やし、癌細胞を認識して攻撃する機能を改善するように設計された医薬品を開発する。   ネクタ―・セラピュ―ティクスは、米国の医薬品開発会社。PEG化と高度なポリマ―接合体技術プラットフォ―ムを利用し、薬剤を開発。同社の薬剤候補ナロキセゴ―ルは、オピオイド誘発性便秘の治療に使われる経口末梢性オピオイド拮抗薬で、非癌性疼痛をもつ患者に使われる。その他、「Etirinotecanペゴル」、「NKTR-181」などがある。   Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The firm focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
本社所在地 455 Mission Bay Boulevard South San Francisco CA 94158 USA
代表者氏名 Robert B. Chess ロバートB.チェス
代表者役職名 Independent Chairman of the Board
電話番号 +1 415-482-5300
設立年月日 33055
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 509人
url www.nektar.com
nasdaq_url https://www.nasdaq.com/symbol/nktr
adr_tso
EBITDA EBITDA(百万ドル) 959.86200
終値(lastsale) 51.79
時価総額(marketcap) 8932157753.67
時価総額 時価総額(百万ドル) 8261.254
売上高 売上高(百万ドル) 1374.129
企業価値(EV) 企業価値(EV)(百万ドル) 6683.524
当期純利益 当期純利益(百万ドル) 902.71300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Nektar Therapeutics revenues increased from $59.3M to $1.13B. Net income totaled $875.7M vs. loss of $123.7M. Revenues reflect License collaboration and other increase from $10.9M to $1.08B Royalty revenue increase of 34% to $19.6M Non-cash royalty revenue related to sale increase of 20% to $16M. Net Income reflects Other income (expense) net increase from $1.6M to $13.7M (income).

 NKTRのテクニカル分析


 NKTRのニュース

   Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript | The Motley Fool  2020/05/08 07:31:06 The Motley Fool
NKTR earnings call for the period ending March 31, 2020.
   Cerus Corporation Announces Strategic Organizational Changes  2020/03/02 21:10:00 Benzinga Feeds
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader Cerus Corporation (NASDAQ: CERS ) today announced the promotion of three key leaders within the Company in anticipation of the Company's expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/ Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire) "These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine," said William ‘Obi' Greenman, Cerus' president and chief executive officer. "Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus' recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise.
   Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for  2020/02/20 17:31:41 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know  2020/02/06 22:50:10 Zacks Investment Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
   Nektar Therapeutics Pullback May Be Short-Lived  2020/01/23 16:43:15 Schaeffers Investment Research
Nektar has struggled to gain momentum since its early August sell-off
   Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript | The Motley Fool  2020/05/08 07:31:06 The Motley Fool
NKTR earnings call for the period ending March 31, 2020.
   Cerus Corporation Announces Strategic Organizational Changes  2020/03/02 21:10:00 Benzinga Feeds
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader Cerus Corporation (NASDAQ: CERS ) today announced the promotion of three key leaders within the Company in anticipation of the Company's expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/ Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire) "These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine," said William ‘Obi' Greenman, Cerus' president and chief executive officer. "Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus' recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise.
   Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for  2020/02/20 17:31:41 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know  2020/02/06 22:50:10 Zacks Investment Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
   Nektar Therapeutics Pullback May Be Short-Lived  2020/01/23 16:43:15 Schaeffers Investment Research
Nektar has struggled to gain momentum since its early August sell-off
   Cerus Corporation Announces Strategic Organizational Changes  2020/03/02 21:10:00 Benzinga Feeds
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader Cerus Corporation (NASDAQ: CERS ) today announced the promotion of three key leaders within the Company in anticipation of the Company's expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/ Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire) "These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine," said William ‘Obi' Greenman, Cerus' president and chief executive officer. "Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus' recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise.
   Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for  2020/02/20 17:31:41 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know  2020/02/06 22:50:10 Zacks Investment Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
   Nektar Therapeutics Pullback May Be Short-Lived  2020/01/23 16:43:15 Schaeffers Investment Research
Nektar has struggled to gain momentum since its early August sell-off
   Why This Opioid Painkiller Is Killing Nektar Therapeutics Stock  2020/01/15 18:06:01 24/7 Wall street

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ネクタ―・セラピュ―ティクス NKTR Nektar Therapeutics)

 twitter  (公式ツイッターやCEOツイッターなど)